Focused On-demand Library for Alpha-2-macroglobulin receptor-associated protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P30533

UPID:

AMRP_HUMAN

Alternative names:

Low density lipoprotein receptor-related protein-associated protein 1

Alternative UPACC:

P30533; D3DVR9; Q2M310; Q53HQ3; Q53HS6

Background:

Alpha-2-macroglobulin receptor-associated protein, also known as Low density lipoprotein receptor-related protein-associated protein 1, plays a crucial role as a molecular chaperone for LDL receptor-related proteins. It is instrumental in regulating their ligand binding activity along the secretory pathway, ensuring proper cellular function and homeostasis.

Therapeutic significance:

Linked to Myopia 23, autosomal recessive, a condition where vision is better for near objects than for far due to the focus of parallel rays from a distant object in front of the retina, this protein's gene variants are pivotal. Understanding the role of Alpha-2-macroglobulin receptor-associated protein could open doors to potential therapeutic strategies for myopia and related refractive errors.